Skinvisible, Inc. (OTC: SKVI)

Skinvisible, Inc. is a pharmaceutical research and development company that has created and patented the polymer delivery system Invisicare and formulated over forty topical skin products which it outlicenses globally.

The company targets the estimated eighty billion dollar global skincare and dermatology market and the thirty billion dollar global over the counter market as well as other healthcare medical and consumer goods markets.

Skinvisible generates revenue primarily through licensing its patented Invisicare enabled prescription and over the counter products to pharmaceutical and consumer goods companies in exchange for upfront fees and ongoing royalties.

The company also earns income from co development services where it assists clients in formulating optimal products for clinical testing and from life cycle management which involves reformulating off patent products with a new Invisicare patent to create line extensions.

Notable license agreements include the exclusive deal with Quoin Pharmaceuticals which provided an upfront fee of one million dollars and entitles Skinvisible to single digit royalties on net sales and a milestone payment upon regulatory approval and the agreement with Ovation Science for the DermSafe hand sanitizer which involved a license fee and royalty payments.

• no_segments_reported.

Skinvisible occupies a specialized niche in the drug delivery sector with its patented Invisicare polymer system which provides extended skin residence and controlled release of active ingredients while the company reports limited direct competition for Invisicare’s performance characteristics many larger firms possess greater financial resources broader product portfolios and stronger brand recognition and competitive advantages stem from the proprietary technology proven to enhance drug delivery reduce irritation and lower required dosages which creates clear scientific and marketing benefits for partners and to remain competitive Skinvisible must continue to invest in sales and marketing though its limited resources may constrain such efforts.

Skinvisible serves pharmaceutical and consumer goods companies worldwide seeking to enhance their topical product offerings and specific licensees disclosed in the filing include Quoin Pharmaceuticals which is developing the Netherton syndrome treatment QRX003 and Ovation Science which markets the DermSafe hand sanitizer product and these relationships illustrate the company’s ability to attract partners interested in leveraging its Invisicare technology for both prescription and over the counter applications.